Exploring Promising Spinal Cord Stimulation Clinical Trials You Can Join Today

Did you know that spinal cord stimulation clinical trials are actively testing ways to directly interrupt pain signals before they reach the brain? These studies implant a small device near the spinal cord that delivers mild electrical pulses, which can significantly reduce chronic pain for conditions like failed back surgery syndrome. The primary benefit participants often report is a dramatic decrease in pain intensity, allowing for better mobility and reduced reliance on opioids.

Mapping the Future: Key Research Directions in SCS Therapy

Mapping the future of SCS therapy is being actively defined by clinical trials exploring closed-loop systems that dynamically adjust stimulation based on real-time neural feedback. Key research now targets leveraging high-resolution imaging to personalize electrode placement, aiming to reduce paresthesia and improve selective fascicle recruitment. Trials focused on sub-perception stimulation are rigorously testing novel waveforms to optimize pain relief without tingling, while others investigate burst patterns for treating axial back pain. A nuanced challenge lies in validating these outcomes across heterogeneous patient populations to ensure robust, generalizable clinical protocols. These practical directions aim to convert trial data into reliable clinical decision-making, directly shaping how clinicians will deploy SCS for maximum patient benefit.

Emerging Indications: Beyond Failed Back Surgery Syndrome

Clinical trials are now rigorously evaluating spinal cord stimulation for chronic refractory angina, peripheral neuropathy, and complex regional pain syndrome, moving beyond the traditional FBSS framework. Early-phase data demonstrate measurable improvements in microcirculation and pain inhibition for these conditions, with protocols specifically targeting non-radicular pain generators. Investigators are optimizing lead placement and frequency parameters to address distinct pathophysiologies, such as ischemic pain versus neuropathic allodynia. These efforts aim to establish SCS as a validated first-line therapy for underserved patient populations, thereby reducing reliance on escalating pharmacotherapy for indications that share no mechanistic overlap with failed back surgery syndrome.

Emerging Indications: Beyond Failed Back Surgery Syndrome reshapes SCS clinical trials toward treating chronic refractory angina, peripheral neuropathy, and complex regional pain syndrome through condition-specific neurostimulation protocols.

High-Frequency vs. Burst Stimulation: Comparative Study Designs

Comparative study designs for high-frequency versus burst stimulation prioritize randomized crossover trials to directly isolate parameter-specific efficacy. Researchers employ double-blind protocols with staggered washout periods, mitigating placebo effects while capturing patient preference data. A critical focus is programming equivalents—matching total charge per second between modalities to ensure fair neural recruitment comparisons. These studies deliberately stratify participants by pain phenotype, as burst’s theorized limbic system modulation may favor affective pain components over high-frequency’s dorsal horn targeting. Endpoints increasingly include objective measures like quantitative sensory testing alongside subjective pain scores. Phenotype-stratified crossover designs are the gold standard for revealing differential mechanisms.

Q: How do crossover designs handle carryover effects in high-frequency versus burst trials?
Extended washout periods (7–14 days) with objective neural monitoring, like contact heat-evoked potentials, verify parameter washout before each stage, ensuring treatment effect isolation.

Closed-Loop Systems: Real-Time Adaptive Stimulation Protocols

Closed-loop systems in SCS trials use real-time biosignal feedback, such as evoked compound action potentials, to dynamically adjust stimulation parameters without patient input. This adaptive protocol ensures precise dosing tailored to moment-by-moment neural state changes, targeting optimal pain relief while minimizing energy use. Early-phase studies focus on validating closed-loop algorithms against standard open-loop therapy, measuring outcomes like paresthesia coverage stability over posture shifts. A critical objective is real-time adaptive stimulation protocols that can autonomously respond to transient spinal cord responses, reducing clinician reprogramming burden and improving long-term efficacy in ambulatory settings.

Navigating the Regulatory Landscape for SCS Studies

Navigating the regulatory landscape for SCS studies demands early alignment with FDA’s IDE pathway, focusing on device modifications and stimulation parameters as pivotal trial endpoints. A key step is classifying your study’s risk—significant risk devices require stringent safety monitoring, while non-significant risk trials may streamline IRB approval. Q: How do I handle long-term data requirements for an SCS trial? A: Plan adaptive follow-up protocols, as regulators often expect durability data beyond six months to validate continued pain relief efficacy without lead migration. Engage with review divisions proactively on sham controls and outcome measure standardization to avoid costly protocol amendments.

FDA Approval Pathways for Novel Lead Geometries

For novel lead geometries in SCS trials, the FDA typically requires a Premarket Approval (PMA) application or a De Novo classification if no predicate exists. Sponsors must submit bench-top, animal, and human data demonstrating safety and effectiveness for the unique geometry, which often necessitates an investigational device exemption (IDE) prior to pivotal studies. Novel lead geometry PMA pathways demand rigorous characterization of stimulation field distribution and mechanical fatigue testing.

Q: What is the most common regulatory hurdle for novel lead geometries? A: Proving substantial equivalence to existing leads is rarely possible, forcing sponsors to generate de novo clinical evidence under an FDA-approved IDE, which significantly extends the premarket timeline.

Ethical Considerations in Sham-Controlled Trial Designs

Sham-controlled trials in SCS research create a genuine ethical tension: you must withhold potentially life-changing therapy from a control group to prove efficacy. The core ethical safeguard is ensuring participants understand they might receive no stimulation, yet still undergo surgery for lead placement. This demands exceptionally clear informed consent, as the sham arm faces real procedural risks without any intended therapeutic benefit. A key question: How do researchers justify implanting hardware without delivering current? The answer rests on rigorous blinding protocols and a mandatory crossover period—typically offering the sham group active stimulation after the blinded phase—so no one is permanently denied potential relief.

Post-Market Surveillance Registries for Long-Term Data

Rather than ending analysis at approval, sponsors deploy post-market surveillance registries for long-term data to track SCS device performance across real-world patient populations. These registries systematically capture how stimulation parameters degrade or hold over years, flagging delayed lead migrations, infection rates, or waning efficacy that short trials miss. Clinicians feed back programming adjustments and adverse events directly into the registry, creating a live dataset that refines patient selection criteria. This continuous loop of evidence—not static follow-ups—lets you justify future revisions to SCS therapy protocols based on actual, sustained outcomes rather than controlled lab conditions.

Post-market surveillance registries for long-term data transform SCS trials from snapshots into living evidence, capturing decade-long real-world outcomes that uncover delayed device faults and guide smarter patient selection.

Patient Selection and Enrollment Strategies

Recruitment for a spinal cord stimulation trial begins by sifting through failed back surgery syndrome patients, where rigorous psychological screening becomes the gatekeeper. One candidate may have ideal pain patterns but carries unmanaged depression; another reports radicular leg pain yet their MRI shows no nerve compression. The enrollment strategy then pivots to matching anatomy with technology—a patient with diffuse axial pain is steered toward a different lead configuration than someone with focal neuropathic burning.

Each enrollment decision hinges on verifying that prior conservative treatments were exhausted while the patient still retains enough functional capacity to operate the device.

I recall one clinic where a technician spent two extra hours with a skittish candidate, using a placebo lead to simulate paresthesia coverage, just to ensure their reported sensory response would align with the study’s implantation criteria.

Psychological Screening as a Predictor of Trial Success

Psychological screening serves as a critical predictor of trial success by identifying candidates with the resilience to manage spinal cord stimulation (SCS) and adhere to trial protocols. Assessments typically evaluate pain catastrophizing, treatment expectations, and emotional stability, as those with untreated psychopathology are more likely to report poor outcomes or device rejection. Predictive value of psychological screening lies in its ability to reduce early dropouts and false-negative efficacy results. Integrating validated tools like the MMPI-2 or BSI-18 during enrollment refines the study cohort, ensuring data reflects true neurostimulation effects.

• Identifies patients at risk of discontinuing the trial due to anxiety or low distress tolerance.
• Filters candidates with unrealistic device expectations that corrupt outcome measurements.
• Detects somatization tendencies that may mimic SCS failure or lead to high placebo response.
• Confirms psychological readiness for repeated programming and diary compliance.

Genetic Biomarkers: Identifying High-Responder Cohorts

Genetic biomarkers help identify high-responder cohorts before a spinal cord stimulation trial even begins. You’d first screen participants for specific gene variants linked to pain processing, like those in sodium channel or opioid receptor pathways. Next, you stratify them into groups based on predicted response probability, ensuring your trial enrolls people most likely to benefit. This reduces noise in outcome data, letting you see actual device effects more clearly. The process typically follows:

1. Collect DNA via saliva or blood samples at screening.
2. Analyze for validated pain-related polymorphisms using a standardized assay.
3. Apply a pre-defined algorithm to assign subjects to high- or low-responder status before randomization.

Managing Placebo Responses in Neuromodulation Research

Managing placebo responses in neuromodulation research requires specific enrollment strategies to isolate device-specific effects from expectation bias. Blinded study designs with low-frequency sub-perception stimulation serve as credible sham comparators, as patients cannot distinguish active from inactive settings. Enrollment must exclude individuals with prior SCS exposure or strong treatment beliefs, verified via validated expectation scales. A sequential approach ensures rigor:

1. Screen candidates using the Stanford Expectations of Treatment Scale to stratify high-placebo responders for exclusion or extended run-in periods.
2. Randomize only after a two-week, single-blinded sham phase to confirm no immediate placebo-driven pain relief exceeding 30%.
3. Mandate real-time symptom diaries to track fluctuation, flagging inconsistent entries as potential confounds.

This methodology minimizes contamination of efficacy endpoints and preserves statistical power.

Endpoint Measurement and Data Integrity

In spinal cord stimulation clinical trials, endpoint measurement reliability directly determines data integrity, as subjective pain scales like VAS must be paired with objective functional outcomes such as gait analysis or medication logs to reduce participant bias. Data integrity hinges on synchronized timestamping of paresthesia mapping results with patient-reported outcomes, ensuring that alterations in stimulation parameters are not conflated with placebo effects. Robust electronic case report forms with built-in range checks and mandatory field completion prevent missing or implausible data, while central review of programming logs verifies that reported device usage matches actual stimulation delivery. This dual focus on consistent endpoint collection and tamper-proof data capture is essential for establishing statistically valid efficacy evidence.

Objective Pain Metrics: Quantitative Sensory Testing in Trials

Quantitative sensory testing in spinal cord stimulation trials provides objective pain metrics by applying calibrated thermal, mechanical, or electrical stimuli to measure sensory thresholds, replacing subjective patient reports. These protocols quantify changes in wind-up ratio and temporal summation, directly capturing central sensitization modifications from therapy. By standardizing stimulus intensity and location across sessions, quantitative sensory testing reduces placebo bias and confirms neurophysiological efficacy within endpoint measurement frameworks. This allows trial designers to correlate stimulation parameters with reproducible sensory gains, strengthening data integrity over ordinal pain scales alone.

Patient-Reported Outcomes Versus Functional Performance Measures

In spinal cord stimulation trials, patient-reported outcomes capture subjective pain relief via numeric scales and quality-of-life instruments, while functional performance measures objectively quantify physical capacity, such as timed walking or sit-to-stand tests. A critical distinction is that patient-reported outcomes may be confounded by placebo response or recall bias, whereas functional performance measures offer verifiable, rater-independent data. The choice between them directly influences endpoint validity; for example, a patient may report 80% pain reduction but show no gain in gait speed. To ensure data integrity, trials often integrate both domains to prevent discrepancy-driven misinterpretation.

• Patient-reported outcomes rely on self-assessment (e.g., VAS for pain), introducing subjectivity that functional performance measures eliminate through standardized task completion.
• Functional performance measures, such as the 6-minute walk test, detect clinically meaningful changes in motor function that patient-reported outcomes may overlook due to habituation.
• Discrepancies between the two require predefined analysis plans to address potential reporting bias or capacity-reality gaps in spinal cord stimulation efficacy.

MRI Compatibility: New Standards for Safety and Artifact Reduction

In spinal cord stimulation clinical trials, MRI conditional system design now mandates rigorous testing to ensure both patient safety and signal fidelity. New artifact reduction algorithms, integrated into the stimulator’s firmware, dynamically adjust pulse parameters during MRI sequences to prevent image distortion around the lead array. This allows for clear visualization of the electrode-tissue interface without repositioning the subject. A critical update involves thermal modeling—modern systems automatically cease stimulation if gradient field heating exceeds a pre-defined delta. Q: How do these new standards handle artifact from the IPG itself? A: They employ real-time k-space correction and passive shimming in the implant casing to nullify ferromagnetic interference, preserving diagnostic-quality scans of adjacent vertebral structures.

Prioritizing Safety and Adverse Event Reporting

In spinal cord stimulation clinical trials, prioritizing safety begins with rigorous adverse event monitoring at every implant and titration phase. Investigators must catalog neurological changes immediately, from electrode migration to sensory dysfunction, using standardized reporting scales within 24 hours of onset. This dynamic vigilance allows for real-time algorithm adjustments, preventing cumulative nerve damage. Patients are coached to recognize and self-report subtle paresthesia anomalies, which are then cross-referenced against device-specific risk databases. Each adverse event report directly feeds into adaptive trial protocols, ensuring that safety triggers halt enrollment or modify stimulation parameters before patterns of harm emerge. This closed-loop system transforms raw incident data into actionable safeguards, keeping participant well-being at the trial’s operational core.

Infection Risk Mitigation in Percutaneous Lead Implantation

Infection risk mitigation in percutaneous lead implantation during spinal cord stimulation clinical trials begins with strict sterile technique and single-use equipment. Preoperative skin antisepsis and prophylactic antibiotics are non-negotiable. Surgeons minimize tissue trauma and operative time to reduce pathogen entry. Prophylactic antibiotic timing is critical, with doses administered precisely 30–60 minutes before incision. The implantation pocket must be small and hemostatic, with no exposed lead loops that could harbor bacteria. Postoperatively, a sterile occlusive dressing remains intact for 72 hours while the patient avoids any moisture near the site. Frequent site checks catch early erythema before it becomes deep infection.

• Mandatory chlorhexidine-alcohol skin prep and nasal decolonization for MRSA carriers.
• Use of antibiotic-impregnated drape adhered to the entire sterile field.
• Short tunneling path with no lead connectors placed directly subcutaneously.
• Post-procedure wound surveillance every eight hours for first 48 hours.

Long-Term Lead Migration Rates Across Different Manufacturers

In spinal cord stimulation clinical trials, long-term lead migration rates across different manufacturers reveal critical differences in device stability. Certain manufacturers’ leads exhibit lower migration incidence over multi-year follow-up, attributed to advanced anchoring designs and flexible paddle configurations. Others show higher displacement rates, particularly in cervical placements, leading to lost paresthesia coverage and requiring reprogramming or revision. These variance in migration rates directly impact clinical trial data integrity, as frequent lead movement confounds pain relief outcomes and adverse event reporting. Patients trialing devices from manufacturers with proven lower long-term migration benefit from sustained therapy, while higher-migration systems necessitate closer radiographic monitoring and more frequent rescue interventions.

Neurological Complications: Monitoring and Mitigation Protocols

In spinal cord stimulation clinical trials, neurological complication surveillance relies on serial quantitative sensory testing and evoked potential monitoring at each dose-escalation visit. Mitigation protocols mandate immediate cessation of stimulation upon detection of new-onset paresthesia in dermatomes beyond the target, followed by impedance verification to rule-out lead migration. Protocols further require pre-defined thresholds for cerebrospinal fluid leak intervention. Post-procedure, automated alerts trigger neurological checks every 15 minutes for the first hour.

• Execute a standardized neurological examination within 30 minutes of any device programming change.
• Maintain a mandatory 2-hour observation period after each amplitude adjustment, with documented motor and sensory mapping.
• Apply a stop-rule algorithm if radicular pain surpasses a visual analog scale score of 4 during intraoperative testing.

Optimizing Trial Protocols for Real-World Applicability

Optimizing trial protocols for spinal cord stimulation (SCS) begins by embedding pragmatic randomization strategies that reflect actual clinical decision-making, such as allowing patients to cross over between stimulation paradigms. Protocols must prioritize extended follow-up periods beyond the standard 12 months to capture device tolerance and real-world parameter drift. Integrating patient-reported outcomes that are sensitive to placebo response and cyclical pain patterns can significantly improve data fidelity. Protocols should also mandate flexible programming windows to mimic clinic-based adjustments, rather than fixed, artificial stimulation settings. Enrolling a heterogeneous sample that excludes overly strict comorbidity criteria ensures findings translate directly to routine practice. Defining a composite endpoint that blends functional gains with reduction in high-dose opioid use further aligns trial design with everyday patient management.

Durable Response Thresholds: Defining Clinically Meaningful Success

When defining durable response thresholds, we’re essentially deciding what “clinically meaningful success” actually looks like for each patient. Rather than using a one-size-fits-all pain score, trials now set individual benchmarks—like at least 50% pain reduction sustained for six months. A clear sequence might be:

1. Identify patient’s baseline pain and functional goals before implant.
2. Set a specific, durable threshold (e.g., ≥50% relief for 12 months).
3. Track if the response holds over time without medication changes.

This way, “success” isn’t just a number spike—it’s a long-term, practical improvement you can actually rely on.

Cost-Effectiveness Analysis in Pivotal SCS Studies

When diving into cost-effectiveness analysis in pivotal SCS studies, you’re essentially checking if the upfront trial investment pays off in real-world value. This analysis typically follows a clear sequence: first, you track direct costs like device price and implantation, then add indirect savings from reduced healthcare visits and pain meds. Next, you measure patient outcomes, often using quality-adjusted life years (QALYs). Finally, you compare the incremental cost-per-QALY against accepted thresholds to justify coverage. thync.com It’s a straightforward way to prove the trial’s practical worth without chasing industry hype.

1. Identify all direct and indirect costs from the trial data.
2. Calculate health gains using QALYs or similar metrics.
3. Compare the cost-per-QALY against payer benchmarks to validate real-world applicability.

Cross-Over Design Challenges in Chronic Pain Populations

Cross-over designs in chronic pain populations for spinal cord stimulation trials face unique hurdles. Patients’ pain often fluctuates unpredictably, making it hard to distinguish a true treatment effect from natural symptom variation. A major issue is carryover effects from prior stimulation, where relief persists into washout periods, corrupting baseline measures. This blunts the data’s ability to show real differences between phases. Patient dropouts are common too, due to discomfort when switching back to sham or no stimulation. So, is a cross-over design still viable here? How do you manage carryover effects when pain relief lingers for weeks? You might extend washout periods or use adaptive randomization, but that raises trial length and complexity.

Technological Innovations Shaping Next-Generation Trials

Next-generation spinal cord stimulation trials are being reshaped by closed-loop systems that dynamically adjust parameters in real-time based on neural feedback. Adaptive algorithms now learn from each patient’s unique pain signature, enabling personalized titration of stimulation frequency and intensity during active movements. This innovation allows trials to measure objective biomarkers—like gait variability or autonomic responses—rather than relying solely on subjective pain scales.

Implantable sensors transmit real-time data on spinal cord potentials, letting researchers correlate stimulation patterns with functional outcomes without requiring prolonged clinic visits.

Simultaneously, high-resolution computational models simulate current spread through individual patient anatomy, reducing trial-and-error programming and accelerating enrollment by demonstrating predictable efficacy early in the study design.

Waveform Personalization via Machine Learning Algorithms

For spinal cord stimulation trials, waveform personalization via machine learning algorithms lets us tweak stimulation patterns in real time based on your feedback. ML models analyze how your pain responds to initial settings, then automatically adjust pulse width, frequency, and amplitude to match your unique nerve activity. The process follows a clear sequence:

1. Collect baseline pain and neural response data during a short test session.
2. Algorithm identifies the most effective waveform features for your specific pain signature.
3. Waveform updates continuously as you report changes in relief or comfort.

This means you get a custom-fit stimulation that evolves with you during the trial, without needing manual re-programming by a clinician.

Wireless Power Transfer: Eliminating Battery Replacement Surgeries

Wireless power transfer directly addresses the primary limitation of current spinal cord stimulators: finite battery life necessitating replacement surgeries. By eliminating the physical battery and internal energy storage, the implanted device can be powered inductively or via ultrasound from an external source worn over the skin. This removes the need for multiple revision procedures to swap depleted batteries, drastically reducing patient risk from repeated surgical interventions. The technology enables a permanent implant architecture where the stimulator’s lifespan is no longer constrained by its power source, allowing clinical trials to focus solely on long-term therapeutic efficacy without the confound of scheduled surgical downtime for power maintenance.

Combination Therapy Trials: SCS with Pharmacogenomic Approaches

Combination therapy trials exploring spinal cord stimulation (SCS) with pharmacogenomic approaches aim to match specific gene variants with stimulator parameters and analgesic drug metabolism. These protocols first sequence patient DNA for CYP450 and opioid receptor polymorphisms, then stratify participants into subgroups based on predicted medication response and pain modulation profiles. A typical sequence involves:

1. Baseline pharmacogenomic screening to identify poor metabolizers or rapid metabolizers of common co-prescribed analgesics.
2. Adaptive SCS programming (frequency, pulse width) tailored to the patient’s genetic pain sensitivity markers.
3. Longitudinal tracking of drug-SCS interaction endpoints, such as opioid sparing or neuroplasticity markers.

This pharmacogenomic SCS personalization directly addresses trial heterogeneity by controlling for genetic confounders in pain relief outcomes.

Global Perspectives and Trial Site Diversity

Global perspectives in spinal cord stimulation clinical trials demand trial site diversity across continents to capture varied patient responses influenced by genetic backgrounds, dietary habits, and baseline pain perception. Sites in North America, Europe, and Asia must use identical stimulation parameters and outcome measures for valid cross-regional comparisons. Recruiting from multiple countries accelerates enrollment and ensures findings reflect real-world efficacy, not just localized demographics. Patients benefit when trial protocols account for region-specific comorbidities like diabetic neuropathy prevalence. Diverse sites also test device compatibility with different healthcare infrastructures, from specialized centers in Germany to rural hospitals in India, improving generalizability of results for global regulatory acceptance.

Regional Differences in Standard of Care for Neuropathic Pain

Regional differences in the standard of care for neuropathic pain directly shape spinal cord stimulation (SCS) trial designs. For example, European protocols often require trialing of conservative therapies—such as gabapentinoids and tricyclic antidepressants—for at least six months before SCS eligibility, while North American guidelines may permit earlier SCS consideration in refractory cases. This divergence affects trial site selection, as a U.S. site may enroll patients with shorter disease duration than a comparable European site, skewing baseline severity. Additionally, Asian regions frequently prioritize low-dose opioid monotherapy over combination pharmacotherapy, altering the comparator arm in SCS studies. Such variability in prior treatments complicates cross-trial outcome comparability and requires stratified analysis for valid site-level interpretation.

Region	Typical Pre-SCS Failed Therapies	Impact on Trial Enrollment
North America	Gabapentinoids, SNRIs, anticonvulsants	Earlier SCS access, shorter pain duration
Europe	Gabapentin, TCAs, tramadol, nerve blocks	Later SCS access, higher disease chronicity
Asia	Low-dose opioids, pregabalin, NSAIDs	Different pharmacologic baseline in control arms

Recruitment Hurdles in Multicenter International Studies

Recruiting subjects for multicenter international spinal cord stimulation trials faces specific hurdles. Divergent patient populations across countries create inconsistent baselines for pain relief outcomes, complicating data pooling. Language barriers and differing cultural attitudes toward implanted devices directly impact informed consent processes and willingness to enroll. Coordinating identical enrollment criteria across international sites is another hurdle, as local clinical norms often dictate disparate inclusion thresholds for pain duration or prior treatment failure. This fragmentation slows recruitment timelines significantly.

Q: What is the primary recruitment hurdle in multicenter international SCS trials?
A: The primary hurdle is ensuring homogenous enrollment criteria across diverse sites, given variations in local clinical standards and patient demographics.

Cultural Variability in Pain Reporting and Study Compliance

In spinal cord stimulation trials, cultural norms directly shape pain reporting, where patients from stoic backgrounds may understate discomfort, while expressive cultures might amplify descriptors, skewing baseline data. This variability impacts study compliance, as divergent attitudes toward medical authority influence adherence to follow-up schedules or device adjustments. Researchers must account for these differences to avoid conflating a site’s cultural response with treatment efficacy. Cultural pain expression variability necessitates adapted patient education and localized communication protocols to ensure uniform compliance across global trial sites.

Aspect	Stoic Cultural Norm	Expressive Cultural Norm
Pain reporting	Underreported intensity	Amplified narrative detail
Study compliance	Higher protocol fidelity due to deference	Lower adherence if instructions conflict with family input

How These Research Studies Test Nerve Pain Relief

What Happens During a Spinal Cord Stimulation Clinical Trial

The Core Mechanism: Electrical Signals Interrupting Pain Pathways

Key Features of Experimental Stimulation Devices

Programmable Waveforms and Frequency Settings

Rechargeable vs. Non-Rechargeable Implant Batteries

MRI Compatibility and Safety Protocols in Trials

Who Qualifies to Participate in These Pain Studies

Common Inclusion Criteria for Candidates

Medical History Conditions That Often Exclude Participants

What Benefits Participants Report During Testing Phases

Reduction in Neuropathic and Failed Back Surgery Pain

Improved Mobility and Reduced Opioid Dependence

Practical Tips for First-Time Trial Volunteers

How to Prepare for the Screening and Baseline Assessment

Questions to Ask the Research Team Before Enrolling

Managing Expectations for the Stimulator Trial Period